In a new pharmaphorum podcast, web editor Nicole Raleigh speaks with Dr Amy Bucher, chief behavioural officer at Lirio, a ...

Months of uncertainty have come to a close. The BIOSECURE Act, now part of the National Defense Authorization Act (NDAA), will put in motion US government-wide restrictions on ‘biotechnology companies ...

Q4 2025 showcased the industry’s pivot toward precise biology, localised delivery, and earlier intervention – with multiple ...

Distilling that complexity into a handful of trends has been no small task. What follows is not a definitive forecast, but ...

The clinical research environment has undergone considerable transformation over the past decade. Protocols are more complex, product pipelines increasingly target smaller and more distributed patient ...

Dermot Kenny, who leads STEM and Research Partnership within Inizio Advisory, shares his journey from bench scientist to CEO, ...

We knew it was coming, and now it’s close. By the end of 2024, the US Food and Drug Administration (FDA) is expected to formally make reviews by a single institutional review board (sIRB) the standard ...

Novo Nordisk has asked the FDA to stop compounding pharmacies making cheaper versions of its semaglutide-based therapies for obesity and diabetes, saying the drug is too complex to be made safely by ...

The Coalition for Epidemic Preparedness Innovations (CEPI), a public-private partnership, is providing up to $54.3 million in ...

Our roundup of financings in the biotech arena this week is led by a $125 million Series A for Ambros Therapeutics, a startup ...

The green light for Rybrevant Faspro – which combines amivantamab with hyaluronidase – means that the drug is the first ...

In a new pharmaphorum podcast, guest Patrick Leung – chief technology officer at Faro Health – discusses how AI can transform clinical trials.